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Glutaric aciduria type 1 (GA1) is a rare, autosomal-recessive organic 
acidaemia. It is caused by deficiency of glutaryl-co-enzyme A (CoA)
dehydrogenase (GCDH) resulting from a mutation in the GCDH gene 
on chromosome 19p13.2. There are 108 known disease-causing 
mutations in the Human Gene Mutation Database.[1] The GCDH 
enzyme is vital in the final degradation of lysine, L-hydroxylysine 
and L-tryptophan. A deficiency of GCDH leads to accumulation of 
glutaric acid (GA) and 3-hydroxyglutarate (3-OHGA) in the brain. 
Neurotoxicity affecting the basal ganglia is caused by mitochondrial 
damage from α-ketoglutarate depletion provoked by excess GA.
The overall global prevalence of GA1 is 1/100 000.[2,3] However, the 
prevalence of the A293T mutation in South African (SA) patients of 
black indigenous ancestry is >1/100 000 and has been documented 
as 1/5 184.[4]
The typical clinical picture of GA1 is that of a developmentally 
normal infant with macrocephaly, who presents with an encephalo-
pathic crisis following an intercurrent illness. The clinical course is 
characterised by neuroregression, dystonia and seizures. Treatment 
comprises a low-lysine diet, carnitine supplementation, and aggres-
sive management of intercurrent illnesses and metabolic crises. Early 
diagnosis is critical, as aggressive management in the presymptomatic 
period prevents progressive neurological damage.
Methods
The main objective of the study was to describe the profile of 
patients with GA1. Furthermore, we sought to raise awareness of the 
condition among health professionals in SA. All patients diagnosed 
with GA1 at Inkosi Albert Luthuli Central Hospital, Durban, SA 
between 2007 and 2015 were included in this study. Diagnosis was 
based on clinical suspicion, followed by the detection of GA in the 
urine, and confirmed on genetic screening for the mutations.
A retrospective review of the inpatient and outpatient electronic 
hospital records was done. The following parameters were evaluated 
at diagnosis: age, gender, premorbid medical history, anthropometry, 
presenting problems, clinical findings and details of management. 
Anthropometric assessment was done by measuring weight, height/
length and head circumference expressed as percentiles and com-
pared with the reference population. All patients were examined by a 
paediatric neurologist. Biochemical data (lactate, ammonia and urine 
organic acid profile) and results of mutational analysis on genetic 
testing were also collated. All neuroimaging was reviewed by a single 
radiologist (AM). The magnetic resonance imaging (MRI) brain pro-
tocol sequences used included: T1-weighted imaging (T1WI) sagittal, 
T2-weighted imaging (T2WI) axial, T2WI fluid attenuated inversion 
recovery (FLAIR) axial, T1WI axial and T2WI coronal, diffusion-
weighted imaging (DWI), apparent diffusion coefficient maps and 
post-contrast T1W1. Information regarding developmental and 
neurological outcomes was obtained at the last follow-up visit.
Statistical analysis of the data was performed using standard 
statistical methods in SPSS version 10.0 (SPSS Inc., USA). 
Ethics approval for the study was obtained from the University 
of KwaZulu-Natal Ethics Committee, and institutional approval was 
obtained from the KwaZulu-Natal Department of Health.
Results
Six patients (4 girls, 2 boys) were identified from our database of 
3 500 clinic patients from 2007 to 2015. Therefore, the prevalence 
of GA1 in our study population was 1.7/1 000 patients. The mean 
age at diagnosis was 12 (range 7 - 22) months. All patients were 
of black African indigenous ancestry. Two children had a history 
of premorbid developmental delay. Four children were diagnosed 
on presentation with an acute encephalopathic crisis following an 
intercurrent infection. Five patients had macrocephaly at presenta-
tion. Five patients had neuroregression after the acute presenta-
tion. The main clinical findings on presentation were: hypotonia 
(n=4), hemiparesis (n=1) and spasticity (n=1). Four children had 
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seizures during their clinical course. Three 
had dystonia and 4 had bulbar dysfunction. 
Four children were treated with antibiotics 
or antiviral medication during the acute 
period for suspected underlying meningitis 
or encephalitis. Long-term therapy included 
anticonvulsants in 4 children (topiramate in 
2 and lamotrigine in 2, respectively) and car-
bidopa in 2. All patients were commenced 
on a lysine-restricted diet, L-carnitine and 
vitamin B6 supplementation. Only 2 patients 
were able to strictly adhere to the diet.
All patients had elevated glutaryl-carnitine 
on urine organic acid screening. The A293T 
mutation is the most commonly described 
gene mutation in South Africans of black 
indigenous ancestry.[4] Patients were screened 
only for the A293T mutation because of 
the high cost of the full mutational analysis. 
Five patients showed a homozygous A293T 
mutation. One patient had a R402W mutation 
that is not commonly described in black 
Africans of indigenous ancestry. There was no 
history of consanguinity in any of our patients. 
Three patients underwent compu ted tomo-
graphy scans of the brain. Two scans showed 
frontotemporal atrophy with destruction of 
the temporal lobes and one scan demonstrated 
hyperdense basal ganglia.
All patients underwent MRI scans of the 
brain on presentation (Table 1). All images 
of patients showed hyperintense basal gan-
glia on T2WI/FLAIR sequences (Fig. 1). 
Four children had enlarged basal ganglia 
and 2 showed atrophy. There was restricted 
diffusion of the basal ganglia on images of 
all patients with enlarged basal ganglia. The 
2 children presenting without encephalopathic 
crises had atrophic ganglia. The thalamus was 
hyperintense in 1 patient. Restricted diffusion 
of the basal ganglia, cerebral peduncles and 
central tegmental tract (Fig. 2) was seen 
on images of all children who presented in 
encephalopathic crises. Restricted diffusion 
on DWI images indicates acute cerebral 
injury. Dysmyelination of the periventricular 
white matter was seen in 1 patient. Six patients 
(Fig. 3) had enlarged cerebrospinal fluid (CSF) 
spaces anterior to the temporal lobes and wid-
ened sylvian fissures, while 3 patients had cor-
tical atrophy. Subdural collections were absent 
in our patients. 
All patients were treated with L-carnitine, 
multi vitamins and a modified diet, with restricted 
leucine and isoleucine. Families were counselled 
about the risk of recurrence, prognosis and need 
for newborn screening in future pregnancies.
On follow-up, 2 patients had a static clini-
cal course with no further regression or 
gain in milestones, 1 has gained milestones 
and is now able to sit unaided at 1 year 
of age. Three children have shown further 
Table 1. Summary of MRI findings
Anatomical 



















Thalami Normal Normal Normal Hyperintense Normal Normal
Cerebral atrophy Absent Absent Present Present Absent Present
White matter Normal Normal Dysmyelination Normal Normal Normal
CST (CP) T2WI↑ T2WI↑ T2WI↑ T2WI↑ Normal T2WI↑
CTT T2WI↑ T2WI↑ T2WI↑ T2WI↑,FLAIR ↑ Normal Normal
Temporal fossae 
CSF spaces and 
sylvian fissures
Enlarged Enlarged Enlarged Enlarged Enlarged Enlarged 
DWI Restricted GP, CP, 
CTT
Restricted BG, CP, 
CTT
Normal Restricted BG, 
CTT, CP
Normal Restricted BG, 
CTT, CP







Fig. 1. A T2W fast-spin echo coronal MRI in 
an 8-month-old child, demon strating enlarged 
hyper intense basal ganglia (globus palladi, cau-
date nucleus and putamina). There is also fronto-








Fig. 2. A DWI (b=1 000) in the same patient as 
in Fig. 1, showing increased signal intensity in the 
cerebral peduncles and widened sylvian fissures.
Fig. 3. A T2W axial MRI in the same patient as 
in Fig. 1, showing enlarged CSF spaces anterior 
to the temporal lobes and hyperintensity in the 
central tegmental tracts bilaterally.
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neuro regression. Of the patients who adhered to the diet, 1 gained 
developmental milestones and 1 has shown a static clinical course. 
The mean age at diagnosis of the children who showed progressive 
disease was higher (16 months) than for those with a non-progressive 
course (8 months).
Discussion
The estimated prevalence of GA1 is 1/100 000 in newborns.[2,3] 
Certain populations, such as the Old Order Amish of Pennsylvania, 
USA,[4] and the Oji-Cree Island Lake First Nation communities of 
Canada,[5] are known to have a higher disease burden. A higher 
carrier rate of the A293T mutation has been previously described 
in patients of black indigenous ancestry in the SA population.[6] 
Heterozygosity for the A293T mutation was found in 1 of 36 unre-
lated black SA newborns, giving a predicted prevalence rate for GA1 
of 1/5 184 in this population.[6] All patients in our cohort were of 
black African indigenous ancestry.
There is no newborn screening programme for GA1 in SA. There-
fore, diagnosis in our patients was after the newborn period when the 
patients were already symptomatic. Early presymptomatic diagnosis 
and focused treatment of GA1 patients lead to a better neurological 
outcome.
The first presentation of GA1 is usually that of an encephalopathic 
crisis following an intercurrent infection in infancy,[7] which occurred 
in 4 of our patients. Our study confirms the findings of a previous 
study that the earlier the age at first crisis, the higher the risk of neu-
rological morbidity.[8] Neuroregression after an acute presentation 
is another common clinical manifestation.[9] This was observed in 
5 of 6 of our patients. The frequency of macrocephaly (83%) in our 
patients was higher than that described in the literature.[10] Seizures 
are an uncommon long-term complication of GA1, which accom-
panies an acute encephalopathic crisis.[11] Four of our patients had 
epilepsy. Sodium valproate should not be used for seizure control in 
patients with GA1, as there have been reports of worsening of the 
control.[11] L-carnitine is used for the treatment of GA1, as it enhances 
excretion of GA. Valproic acid reduces the levels of L-carnitine and 
competes with GA for esterification with L-carnitine. Valproic acid 
also causes relative L-carnitine deficiency, as it is excreted in the 
urine as valproyl carnitine. The mechanism of valproate toxicity is 
purported to be via interference with mitochondrial beta oxidation.[12] 
Neurotoxicity in GA1 is also mediated through mitochondrial injury. 
Three of our patients had a movement disorder. Dystonia has been 
reported to occur frequently in other case series.[13] The severity of 
dystonia correlates with the extent of striatal injury.[14]
With regard to diet, lysine restriction, carnitine supplementation 
and aggressive management of intercurrent illness with additional 
glucose significantly reduce the frequency of acute encephalopathic 
crises and long-term morbidity.[8] All our patients were commenced on 
carnitine and multivitamin supplementation. Dietary lysine restriction 
was initiated in all patients. However, only 2 patients were able to strictly 
adhere to their diet prescription. The caregivers of the remaining patients 
declined the prescribed restrictive diet because of cultural preferences. 
The most common abnormality seen on MRI as described in the 
literature is widening of the CSF spaces anterior to the temporal lobes 
and of the sylvian fissures,[14] which was seen in all our patients.
Acute encephalopathy is typically associated with acute striatal 
necrosis. Patients with striatal injury develop movement disorders. 
Our patients showed features of acute injury to the basal ganglia at 
the time of the acute encephalopathic crises, as evidenced by enlarged 
basal ganglia with restricted diffusion. 
DWI is an MRI sequence used to detect diffusivity of water mol-
ecules. Restricted diffusion of extracellular fluid is a result of cytotoxic 
oedema, which occurs after acute neuronal injury. DWI detects basal 
ganglia injury earlier and more accurately than conventional MRI 
sequences.[15] Diffusion-weighted MRI could lead to earlier detection of 
patients with GA1. Early intervention after detection of acute injury on 
DWI could result in better long-term outcomes in patients with GA1. 
White matter changes involving the deep periventricular white 
matter are described in patients with GA1.[16] These changes are 
seen more commonly in patients with late-onset disease. One of our 
patients showed dysmyelination. Signal change in the central tegmen-
tal tract is described in the literature in up to 50% of children and 
was seen in 66% of our patients.[14] Furthermore, signal changes of 
T2 hyperintensity and DWI in the corticospinal tracts of the cerebral 
peduncles were seen in 4 patients who presented in acute encepha-
lopathic crises. 
GA1 is a heterogeneous disease. The R402W mutation is the most 
common mutation in white people.[17] The majority of our patients 
(83%) tested positive for the A293T mutation, which is the most 
common mutation in the indigenous black SA population.[6] 
Children diagnosed early with GA1 and thereafter started on treat-
ment had better long-term outcomes. Initiation of dietary modifica-
tion after the onset of symptoms was not effective in preventing per-
manent neurological injury. However, treatment prevents progressive 
neurological deterioration. 
Recommended screening for GA1
This comprises an organic acid profile in urine by means of urine 
metabolic screening. The diagnosis can be confirmed by testing for 
the A293T mutation of the GCDH gene, which can be done at the 
National Health Laboratory Service.
Conclusion
GA1 is an important, treatable neurometabolic disorder with a high 
prevalence (1.7/1 000) in the SA population. Although the limita-
tions of this study were the small number of patients and that it was 
retrospective, it is the first study in Africa to analyse the neuroimag-
ing correlates in GA1. GA1 is probably being underdiagnosed. In the 
absence of a newborn screening programme, a high index of clinical 
suspicion is mandatory for affected children to be identified early. 
Early diagnosis and implementation of appropriate therapy result in 
better neurological outcomes.
This study highlights the urgent need for a newborn screening 
programme to be implemented in SA. Our study also forms the basis 
for a long-term multisite collaborative study on GA1 in SA.
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